Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209462) titled 'Study of MRM-3379 in Male Participants With Fragile X Syndrome' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Mirum Pharmaceuticals, Inc.
Condition:
Fragile X Syndrome
Intervention:
Drug: Low dose of MRM-3379
Drug: Middle Dose of MRM-3379
Drug: High dose of MRM-3379
Drug: Placebo
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: December 2025
Target Sample Size: 60
Countries of Recruitment:
United States
To know more, vis...